Reata Pharmaceuticals Inc. announced the outcome of the U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting on bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome.
Eight years ago, a group of scientists began to carefully repeat early laboratory experiments in cancer research that had much influence on the field. In their study, they recreated 50 experiments and found that 54% of the studies could not be reproduced. The results were published in eLife, a nonprofit that receives funding from the Howard Hughes Medical Institute.
Pfizer and BioNTech say three doses of their Covid-19 vaccine can neutralize the newly discovered Omicron variant of the SARS-CoV-2 virus.
Neurocrine Bioscience and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.
The Omicron variant can partially evade protection from two doses of Pfizer and partner BioNTech’s Covid-19 vaccine, the research head of a laboratory at the Africa Health Research Institute in South Africa said on December 7.
Carlsbad, Calif.-based Ionis Pharmaceuticals inked a collaboration deal with AstraZeneca to develop and commercialize eplontersen for transthyretin amyloidosis (ATTR).
The shares of Utah-based Recursion climbed on December 7 after the company announced entering into a “transformational collaboration” with Swiss pharma giant Roche valued in the billions of dollars to identify and develop up to 40 new medications for neuroscience and oncology.
EU health agencies recommended that Covid-19 vaccines be mixed and matched for both initial courses and booster doses as the region battles rising cases ahead of Christmas.
Boston-based Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from the company’s pipeline and discovery platform.
Shares of vTv Therapeutics climbed in trading on December 7 after the company announced plans to restructure and reduce head count by 65 percent in order to ensure funding for a Phase III trial for lead diabetes program TTP399.